Drug
Inetetamab clinical trials
- studies test it
- 12
- open now
- 7
- in phase 3
- 1
- first study started
- 2020
Keep track of what changes. Save the Inetetamab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
12 studies that test it; most in 2021 (5)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 4 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 8
- Phase 3
- 1
- Phase 4
- 2
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 12
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2) · Xijing Hospital (1) · Fujian Medical University (1) · Chinese Academy of Medical Sciences (1) · Peking Union Medical College (1) · Fudan University (1) · Wang Ouchen (1) · The First Affiliated Hospital with Nanjing Medical University (1)
Often tested with
Tested in the same studies.
Pyrotinib (5) · Paclitaxel (3) · Albumin-Bound Paclitaxel (2) · Sirolimus (1) · Sacituzumab tirumotecan (1) · Docetaxel (1) · Carboplatin (1) · Vinorelbine (1)
Studies
Open first, then newest update. How each study uses Inetetamab is read from its arms, and is right about nine times in ten.
Testing it · 12
- SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd TreatmentRecruitingPhase 2Fudan UniversityNCT07182721Written as SKB264 Plus Inetetamab
- The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast CancerRecruitingPhase 4Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06641544Written as Inetetamab
- A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast CancerRecruitingNot applicableWang OuchenNCT06234137Written as Inetetamab
- Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast CancerRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT05823623Written as Inetetamab
- A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast CancerNot yet recruitingPhase 2Fujian Medical UniversityNCT05621434Written as Inetetamab, pyrotinib, chemotherapy
- Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast CancerNot yet recruitingPhase 4Chinese Academy of Medical SciencesNCT05291910Written as Inetetamab
- Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM PathwayNot yet recruitingPhase 3Peking Union Medical CollegeNCT04736589Written as Inetetamab
- Neoadjuvant Inetetamab and Pyrotinib and Nab-paclitaxel for HER2+Breast CancerCompletedPhase 2Xijing HospitalNCT05444998Written as Inetetamab, pyrotinib, nab-paclitaxel
- Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast CancerStatus unknownPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT05749016Written as inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP) regimen
- Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung CancerStatus unknownPhase 1/2Sun Yat-sen UniversityNCT05016544Written as inetetamab
- Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast CancerStatus unknownPhase 2Zhiyong YuNCT04963595Written as Inetetamab
- Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast CancerStatus unknownPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT04681911Written as Inetetamab
Given in every arm · 2 — Inetetamab is usual care beside what is tested
- RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC FailureNot yet recruitingPhase 2/3Fudan UniversityNCT07366840Written as Inetetamab
- Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)Active, not recruitingPhase 2Henan Cancer HospitalNCT05328440Written as Inetetamab